Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

about

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

Item

http://www.wikidata.org/entity/Q58738654

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@en

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@nl

type

Item

label

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@en

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@nl

prefLabel

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@en

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@nl

P1476

Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

@en

P2093

Christoph Pöttgen

http://www.w3.org/2001/XMLSchema#string

Frank Griesinger

http://www.w3.org/2001/XMLSchema#string

Julia Roeper

http://www.w3.org/2001/XMLSchema#string

Kay C Willborn

http://www.w3.org/2001/XMLSchema#string

Wilfried E E Eberhardt

http://www.w3.org/2001/XMLSchema#string

P2860

Whole brain radiotherapy for the treatment of multiple brain metastases

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

P304

35181-35194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.26073

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30416687

http://www.w3.org/2001/XMLSchema#string

P932

6205553

http://www.w3.org/2001/XMLSchema#string